Michael Whalen, MD
Urology · Washington, DCNPI 1164675245
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 23.9%. 2025 is the largest year on record at $10,133, more than ten times the $896 reported in 2019.
Across 86 payments — averaging $201.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- Ferring Pharmaceuticals Inc.$4K
- Intuitive Surgical$3K
- Urogen Pharma, Inc.$3K
- Angiodynamics, Inc.$1K
- Johnson & Johnson$444
- plus $2K from 26 others
What the payments were for
- Consulting fees$3,48220%
- Speaking & faculty fees$6,40037%
- Travel & lodging$2,52715%
- Food & beverage$4,11924%
- Education$7704%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $4,143 |
| Ferring Pharmaceuticals Inc. | 4 | $3,777 |
| Intuitive Surgical | 11 | $2,646 |
| Urogen Pharma, Inc. | 9 | $2,640 |
| Angiodynamics, Inc. | 5 | $1,331 |
| Johnson & Johnson(3 entities) | 10 | $444 |
| Agiliti Surgical, Inc. | 3 | $300 |
| Photocure Inc | 3 | $283 |
| Dendreon Pharmaceuticals LLC | 4 | $172 |
| Immunitybio, Inc. | 1 | $162 |
| Acera Surgical, Inc. | 1 | $161 |
| Profound Medical Corp. | 1 | $134 |
| Tempus AI, Inc | 2 | $133 |
| Astellas Pharma US Inc | 3 | $126 |
| Blue Earth Diagnostics | 1 | $121 |
| Pacira Pharmaceuticals Incorporated | 1 | $121 |
| AstraZeneca | 1 | $99 |
| Galvanize Therapeutics, Inc | 1 | $69 |
| Myovant Sciences Inc. | 3 | $61 |
| Boston Scientific | 2 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Olympus America Inc. | 2 | $38 |
| Lantheus Medical Imaging, Inc. | 1 | $36 |
| AbbVie | 1 | $35 |
| Syndax Pharmaceuticals, Inc. | 1 | $32 |
| Tolmar, Inc. | 1 | $28 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| BD | 1 | $24 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Palette Life Sciences, Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Mission Pharmacal Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGOVYX$4,000
- ADSTILADRIN$3,753
- Da Vinci Surgical System$1,846
- Nanoknife$1,287
- DAVINCI XI$750
- ANKTIVA$162
- Restrata Wound Matrix$161
- Tulsa-Pro$134
- JELMYTO$130
- Axumin$121
- EXPAREL$121
- PROVENGE$119
- Cysview$114
- Sonablate HIFU$113
How this compares
$17,306 in reported general payments places this provider in the 85th percentile of 47 urology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 183 | $592,087 |
| Abiraterone Acetate | 24 | $209,892 |
| GemtesaVibegron | 18 | $21,995 |
| MyrbetriqMirabegron | 13 | $15,107 |
| Silodosin | 44 | $4,691 |
| Tamsulosin Hcl | 180 | $3,348 |
| Finasteride | 52 | $809 |
| Dutasteride | 14 | $715 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $232 |
| Prednisone | 16 | $194 |
| Ciprofloxacin Hcl | 13 | $142 |
| CefuroximeCefuroxime Axetil | 13 | $106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $46 | $614,082201 claims |
| Astellas Pharma US IncMyrbetriq | $126 | $15,10713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 47 urology providers in District of Columbia.
Other urology in Washington
- Armine SmithWashington$58K
- Nathan ShawWashington$54K
- Lambros StamatakisWashington$39K
- Patrick MufarrijWashington$31K
- Ryan HankinsWashington$29K
- Adam MetwalliWashington$27K
- Pamela ColemanWashington$14K
- Leslie DeaneWashington$13K
- Jason EngelWashington$12K
- Keith KowalczykWashington$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.